To the Clarity Male Breast Cancer Study Information Page
To learn more about the study, call (800) 713-6818
Treatment option for male breast cancer
The Male Breast Cancer study is currently enrolling patients across the U.S. Contact us today to find a participating clinic near you.
Innocrin Pharmaceuticals' clinical study INO-VT-464-CL-006 is evaluating the safety, tolerability, pharmacokinetics and activity of seviteronel (VT-464),
a lyase-selective inhibitor of CYP17 and androgen receptor antagonist,
in men with advanced breast cancer.
A number of factors can increase a man's risk of getting breast cancer including but not limited to:
Did You Know?
About 2,000 men are diagnosed
with breast cancer each year.